Mohamed Baana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Baana has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Eva Bolton
Department of Urology, Imperial College Healthcare NHS Trust, London, UK
1 shared publication- Eva Bolton
Imperial College London NHS Trust, London, UK
1 shared publication Gaurika Bhardwaj
Department of Urology, Imperial College Healthcare NHS Trust, London, UK
1 shared publication- Gaurika Bhardwaj
Imperial College London NHS Trust, London, UK
1 shared publication Mariam Lami
Department of Urology, Imperial College Healthcare NHS Trust, London, UK
1 shared publication- Mariam Lami
Imperial College London NHS Trust, London, UK
1 shared publication
Latest Publications
- Open Access
Utilisation of artificial intelligence to enhance the detection rates of renal cancer on cross-sectional imaging: protocol for a systematic review and meta-analysis
Introduction The incidence of renal cell carcinoma has steadily been on the increase due to the increased use of imaging to identify incidental masses. Although survival has also improved because of early detection, overdiagnosis and overtreatment of benign renal masses are associated with significant morbidity, as patients with a suspected renal malignancy on imaging undergo invasive and risky procedures for a definitive diagnosis. Therefore, accurately characterising a renal mass as benign or malignant on imaging is paramount to improving patient outcomes. Artificial intelligence (AI) poses an exciting solution to the problem, augmenting traditional radiological diagnosis to increase detection accuracy. This report aims to investigate and summarise the current evidence about the diagnostic accuracy of AI in characterising renal masses on imaging. Methods and analysis This will involve systematically searching PubMed, MEDLINE, Embase, Web of Science, Scopus and Cochrane databases. Publications of research that have evaluated the use of automated AI, fully or to some extent, in cross-sectional imaging for diagnosing or characterising malignant renal tumours will be included if published between July 2016 and June 2025 and in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score will be used to evaluate the quality and risk of bias across included studies. Furthermore, in line with Checklist for Artificial Intelligence in Medical Imaging recommendations, studies will be evaluated for including the minimum necessary information on AI research reporting. Ethics and dissemination Ethical clearance will not be necessary for conducting this systematic review, and results will be disseminated through peer-reviewed publications and presentations at both national and international conferences. PROSPERO registration number CRD42024529929.
Open AccessUtilisation of artificial intelligence to enhance the detection rates of renal cancer on cross-sectional imaging: protocol for a systematic review and meta-analysis
Introduction The incidence of renal cell carcinoma has steadily been on the increase due to the increased use of imaging to identify incidental masses. Although survival has also improved because of early detection, overdiagnosis and overtreatment of benign renal masses are associated with significant morbidity, as patients with a suspected renal malignancy on imaging undergo invasive and risky procedures for a definitive diagnosis. Therefore, accurately characterising a renal mass as benign or malignant on imaging is paramount to improving patient outcomes. Artificial intelligence (AI) poses an exciting solution to the problem, augmenting traditional radiological diagnosis to increase detection accuracy. This report aims to investigate and summarise the current evidence about the diagnostic accuracy of AI in characterising renal masses on imaging. Methods and analysis This will involve systematically searching PubMed, MEDLINE, Embase, Web of Science, Scopus and Cochrane databases. Publications of research that have evaluated the use of automated AI, fully or to some extent, in cross-sectional imaging for diagnosing or characterising malignant renal tumours will be included if published between July 2016 and June 2025 and in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score will be used to evaluate the quality and risk of bias across included studies. Furthermore, in line with Checklist for Artificial Intelligence in Medical Imaging recommendations, studies will be evaluated for including the minimum necessary information on AI research reporting. Ethics and dissemination Ethical clearance will not be necessary for conducting this systematic review, and results will be disseminated through peer-reviewed publications and presentations at both national and international conferences. PROSPERO registration number CRD42024529929.
- Open Access
Using artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: a protocol for a systematic review and meta-analysis
Introduction Cystoscopy has revolutionised the process of diagnosing bladder cancer leading to better categorisation of risk levels and more precise treatment plans. Nonetheless, concerns arise about the lack of uniformity among observers in predicting tumour stage and grade. To address these concerns, artificial intelligence (AI) is being incorporated into clinical settings to aid in the analysis of diagnostic and therapeutic images. The subsequent report outlines a systematic review and meta-analysis protocol aimed at evaluating the effectiveness of AI in predicting bladder cancer based on cystoscopic images. Methods and analysis Our systematic search will use databases including PubMed, MEDLINE, Embase and Cochrane. The articles published between May 2015 and April 2024 will be eligible for inclusion. For articles to be considered, they must employ AI for analysis of cystoscopic images to identify bladder cancer, present original data and be written in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol 2015 checklist. Quality and bias risk across chosen studies will be evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Ethics and dissemination Ethical clearance will not be necessary for conducting this systematic review since results will be disseminated through peer-reviewed publications and presentations at both national and international conferences. PROSPERO registration number CRD42024528345.
Open AccessUsing artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: a protocol for a systematic review and meta-analysis
Introduction Cystoscopy has revolutionised the process of diagnosing bladder cancer leading to better categorisation of risk levels and more precise treatment plans. Nonetheless, concerns arise about the lack of uniformity among observers in predicting tumour stage and grade. To address these concerns, artificial intelligence (AI) is being incorporated into clinical settings to aid in the analysis of diagnostic and therapeutic images. The subsequent report outlines a systematic review and meta-analysis protocol aimed at evaluating the effectiveness of AI in predicting bladder cancer based on cystoscopic images. Methods and analysis Our systematic search will use databases including PubMed, MEDLINE, Embase and Cochrane. The articles published between May 2015 and April 2024 will be eligible for inclusion. For articles to be considered, they must employ AI for analysis of cystoscopic images to identify bladder cancer, present original data and be written in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol 2015 checklist. Quality and bias risk across chosen studies will be evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Ethics and dissemination Ethical clearance will not be necessary for conducting this systematic review since results will be disseminated through peer-reviewed publications and presentations at both national and international conferences. PROSPERO registration number CRD42024528345.